Opinion|Videos|November 11, 2024
Treatment Approaches for Patients With Oligodendrogliomas and Grade 2 Gliomas
Author(s)Vinay K. Puduvalli, MD
Panelists discuss how they tailor treatment strategies for oligodendrogliomas and Grade 2 gliomas based on key clinical and molecular markers, with particular attention to insights from the CODEL trial and RTOG 9802 study.
Advertisement
Episodes in this series
- How do you approach treatment decisions for patients with oligodendrogliomas and Grade 2 gliomas? What clinical and molecular factors most significantly influence your approach?
- CODEL TRIAL
- RTOG 9802
Advertisement
Related to this article
Ethan B. Ludmir, MD, explains why advanced radiation techniques like protons fit nonoperative cholangiocarcinoma better than the preoperative setting.
10-year CHN HYPOPMRT data show 3-week postmastectomy RT with nodal irradiation maintains locoregional control without added severe late toxicity.
Ayal Aizer, MD, MHS, explains why fractionated SRS outperformed single-fraction SRS for surgical bed control in Alliance A071801.
Andy Liao, MD, discusses KRAS-targeted strategies, molecular profiling, multidisciplinary care, and FGFR2 inhibitor sequencing in cholangiocarcinoma.
“To me, the biggest differentiator might be how the patient wants to experience care,” said Krish Patel, MD, on treatment options for patients with lymphoma.
Ayal Aizer, MD, MHS, says Alliance A071801 supports fractionated SRS as standard after resection, with comparable radiation necrosis rates.
Jyoti Malhotra, MD, MPH on first-in-human clinical trials, lung cancer precision medicine in 2026, the disparities tension in drug development, and her move to Yale Cancer Center.
A personalized ctDNA assay demonstrated 100% specificity but limited sensitivity for detecting recurrence after liver transplantation in HCC and CCA.
Advertisement
Advertisement
Trending on CancerNetwork
1
Distal Extrahepatic Cholangiocarcinoma May Gain From Neoadjuvant Radiation
2
Neoadjuvant Radiation May Improve Tolerability in Cholangiocarcinoma
3
Hydrogel Spacer Receives FDA 510(k) Clearance for Prostate Cancer Radiotherapy
4
PDS0101/Pembrolizumab Yields 39.3-Month Median OS in HPV16-Positive HNSCC
5